vs
Side-by-side financial comparison of Recon Technology, Ltd (RCON) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $12.2M, roughly 1.7× Recon Technology, Ltd). Recon Technology, Ltd runs the higher net margin — -6.8% vs -84.4%, a 77.5% gap on every dollar of revenue. On growth, Recon Technology, Ltd posted the faster year-over-year revenue change (111.0% vs -65.2%).
Recon Instruments Inc. was a Canadian technology company that produced smartglasses and wearable displays marketed by the company as "heads-up displays" for sports. Recon's products delivered live activity metrics, GPS maps, and notifications directly to the user's eye. Recon's first heads-up display offering was released commercially in October 2010, roughly a year and a half before Google introduced Google Glass.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
RCON vs TRDA — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.2M | $20.6M |
| Net Profit | $-832.7K | $-17.3M |
| Gross Margin | 33.5% | — |
| Operating Margin | -14.6% | -106.0% |
| Net Margin | -6.8% | -84.4% |
| Revenue YoY | 111.0% | -65.2% |
| Net Profit YoY | 70.5% | -173.8% |
| EPS (diluted) | $-0.09 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.2M | — | ||
| Q1 25 | — | $20.6M | ||
| Q4 24 | $5.8M | $37.4M | ||
| Q3 24 | — | $19.6M | ||
| Q2 24 | — | $94.7M | ||
| Q1 24 | — | $59.1M | ||
| Q4 23 | $6.4M | $41.8M | ||
| Q3 23 | — | $43.7M |
| Q4 25 | $-832.7K | — | ||
| Q1 25 | — | $-17.3M | ||
| Q4 24 | $-2.8M | $1.1M | ||
| Q3 24 | — | $-14.0M | ||
| Q2 24 | — | $55.0M | ||
| Q1 24 | — | $23.5M | ||
| Q4 23 | $-3.2M | $-9.5M | ||
| Q3 23 | — | $35.5M |
| Q4 25 | 33.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 31.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 26.7% | — | ||
| Q3 23 | — | — |
| Q4 25 | -14.6% | — | ||
| Q1 25 | — | -106.0% | ||
| Q4 24 | -63.9% | -15.7% | ||
| Q3 24 | — | -110.7% | ||
| Q2 24 | — | 56.4% | ||
| Q1 24 | — | 35.7% | ||
| Q4 23 | -50.4% | 11.7% | ||
| Q3 23 | — | 32.0% |
| Q4 25 | -6.8% | — | ||
| Q1 25 | — | -84.4% | ||
| Q4 24 | -48.9% | 3.0% | ||
| Q3 24 | — | -71.7% | ||
| Q2 24 | — | 58.1% | ||
| Q1 24 | — | 39.7% | ||
| Q4 23 | -49.8% | -22.8% | ||
| Q3 23 | — | 81.1% |
| Q4 25 | $-0.09 | — | ||
| Q1 25 | — | $-0.42 | ||
| Q4 24 | $-0.31 | $-0.20 | ||
| Q3 24 | — | $-0.35 | ||
| Q2 24 | — | $1.55 | ||
| Q1 24 | — | $0.68 | ||
| Q4 23 | $-1.16 | $-0.23 | ||
| Q3 23 | — | $1.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.7M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $66.4M | $417.3M |
| Total Assets | $77.6M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.7M | — | ||
| Q1 25 | — | $67.8M | ||
| Q4 24 | $19.9M | $101.2M | ||
| Q3 24 | — | $78.0M | ||
| Q2 24 | — | $185.3M | ||
| Q1 24 | — | $68.4M | ||
| Q4 23 | $36.0M | $67.6M | ||
| Q3 23 | — | $51.9M |
| Q4 25 | $66.4M | — | ||
| Q1 25 | — | $417.3M | ||
| Q4 24 | $66.9M | $428.7M | ||
| Q3 24 | — | $422.4M | ||
| Q2 24 | — | $429.9M | ||
| Q1 24 | — | $269.4M | ||
| Q4 23 | $60.0M | $242.4M | ||
| Q3 23 | — | $246.7M |
| Q4 25 | $77.6M | — | ||
| Q1 25 | — | $486.5M | ||
| Q4 24 | $74.2M | $526.3M | ||
| Q3 24 | — | $554.6M | ||
| Q2 24 | — | $582.0M | ||
| Q1 24 | — | $510.8M | ||
| Q4 23 | $68.1M | $469.2M | ||
| Q3 23 | — | $485.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.9M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.9M | — | ||
| Q1 25 | — | $-38.5M | ||
| Q4 24 | $-1.7M | $-31.6M | ||
| Q3 24 | — | $-24.3M | ||
| Q2 24 | — | $39.8M | ||
| Q1 24 | — | $-25.5M | ||
| Q4 23 | $-931.0K | $-4.0M | ||
| Q3 23 | — | $-24.5M |
| Q4 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M | ||
| Q4 23 | — | $-5.0M | ||
| Q3 23 | — | $-25.9M |
| Q4 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% | ||
| Q4 23 | — | -11.9% | ||
| Q3 23 | — | -59.3% |
| Q4 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% | ||
| Q4 23 | — | 2.3% | ||
| Q3 23 | — | 3.3% |
| Q4 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -0.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
